Overview

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Status:
Not yet recruiting

Trial end date:
2031-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without EGFR-sensitizing mutations and ALK fusions after complete surgical resection.The subjects were randomly divided into two groups according to 1:1, with about 316 subjects in the experimental group and the control group.

Phase:

Phase 3

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.

Treatments:

Carboplatin
Paclitaxel
Pemetrexed
Vinorelbine